Selective Serotonin Reuptake Inhibitor

Selective Serotonin Reuptake Inhibitor - most related articles:

- Paradoxical effect of certain antidepressants discovered - 7.6
- Antidepressant drugs may lead to lactation difficulties in moms - 7.5
- New target for antidepressants for depression and anxiety - 7.4
- Antidepressants in pregnancy increase miscarriage risk - 7.2
- Antidepressant may prevent heart failure - 6.9
- Milnacipran for management of fibromyalgia approved - 6.5
- Antidepressant and psychotherapy work for depressed teens - 6
- Lack of evidence for antidepressants in Autism - 5.7
- Positive clinical trial results of vilazodone for depression - 5.5
- Brain and genes to improve anxiety treatment - 5.3

Selective Serotonin Reuptake Inhibitor articles

Antidepressant may prevent heart failure
A medication usually used to help treat depression and anxiety disorders has the potential to help prevent heart failure. John Tesmer, research professor at the U-M Life Sciences Institute and professor in the Department of Pharmacology at the U-M Medical School, and his research team at the Tesmer lab found that paroxetine, a selective serotonin reuptake inhibitor (SSRI) sold under the name Paxil, inhibits G protein-coupled receptor kinase 2 (GRK2), a protein kinase that becomes over-expressed when people have heart failure.

Anti inflammatory drugs reduce effectiveness of SSRI antidepressants
Anti-inflammatory drugs, which include ibuprofen, aspirin and naproxen, reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors, or SSRIs, taken for depression and obsessive-compulsive disorder and anxiety disorders.

Lack of evidence for antidepressants in Autism
Antidepressants commonly prescribed to people with autistic spectrum disorders cannot be recommended based on current evidence, revealed by Cochrane Researchers.

Antidepressant drugs may lead to lactation difficulties in moms
Women taking commonly used forms of antidepressant drugs may experience delayed lactation after giving birth and may need additional support to achieve their breastfeeding goals.

Positive clinical trial results of vilazodone for depression
Clinical Data, Inc. (NASDAQ: CLDA) announced positive top-line results from the second of two Phase III trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD).

5 Selective Serotonin Reuptake Inhibitor articles listed above.


Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.
Subscribe: rss | email

Top sections:
Health (188)
Breast cancer (168)
Healthcare (134)
HIV (129)
Obesity (126)
Pregnancy (114)
Diabetes (101)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (84)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (52)


List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2014 HealthNewstrack.com
2.07